FDA Approves Belzutifan-Lenvatinib Combo for Kidney Cancer

Belzutifan + lenvatinibWhat to know

30-second read

For Oncology · Urology

Who

Advanced clear-cell renal cell carcinoma that progressed on or after a PD-1/PD-L1 inhibitor, or within six months of finishing adjuvant PD-1 therapy.

What’s new

First approved regimen pairing a HIF-2α inhibitor (belzutifan) with a multitargeted TKI (lenvatinib) in the post-immunotherapy setting.

Evidence

LITESPARK-011 (747 patients) vs. cabozantinib alone: PFS 14.8 vs. 10.7 months (HR 0.70, p=0.00007); response 53% vs. 40%.

Big advantage

A materially higher response rate than cabozantinib alone, in a setting with limited options once immunotherapy has failed.

Key consideration

No significant survival benefit yet (HR 0.85, CI crosses 1.0); higher discontinuation for toxicity than cabozantinib, plus belzutifan's hypoxia/anemia monitoring.

Availability

Approved 24 September 2026. Both drugs are already separately marketed and reimbursed for other indications; combined pricing and payer policy for this label are not yet public.

Practice impactConsider — no survival benefit shown

A real gain in tumor control over cabozantinib alone, but not yet a proven survival advantage, and it adds toxicity to an already-toxic class. Discuss the trade-offs; this isn't an automatic switch while guidelines and payers catch up.

Read the full physician analysis

Full analysis · 7 min readFDA approval notice, 24 September 2026 · LITESPARK-011 (published data) · NCCN Kidney Cancer guideline update, 2026

FDA approved belzutifan (Welireg) in combination with lenvatinib (Lenvima) on 24 September 2026 for adults with advanced clear-cell renal cell carcinoma whose disease progressed after a PD-1 or PD-L1 inhibitor — the first approved regimen pairing a HIF-2α inhibitor with a multitargeted TKI in this post-immunotherapy setting. Both drugs were already on the market individually. What's new is permission to use them together, on the strength of a trial that beat its comparator cleanly on tumor control but has not yet shown it extends survival — a distinction oncologists will need to hold onto as the combination reaches the clinic ahead of any guideline placement.

Two Established Drugs, One New Combination

Belzutifan is already approved as monotherapy for certain von Hippel-Lindau-associated tumors and, since 2023, for previously treated advanced clear-cell RCC on its own. Lenvatinib is a familiar multitargeted TKI in renal and thyroid cancer, most often prescribed today alongside a checkpoint inhibitor earlier in treatment. What this approval adds is the specific pairing, in the specific setting of disease that has already progressed on a checkpoint inhibitor — a point at which oncologists have typically reached for cabozantinib alone, cabozantinib plus nivolumab, or another TKI-based regimen. Merck and Eisai's rationale, echoed in both companies' materials, is that HIF-2α inhibition and VEGFR-pathway blockade work through genuinely distinct mechanisms, which is the argument for combining them rather than simply substituting one TKI-based regimen for another.

The Trial's Big Number, and Its Missing One

LITESPARK-011 randomized 747 patients with advanced clear-cell RCC, all previously treated with anti-PD-1/PD-L1 therapy, to belzutifan plus lenvatinib or to cabozantinib alone. The progression-free survival result is decisive: a median of 14.8 months against 10.7 months for cabozantinib, a hazard ratio of 0.70 with a tight confidence interval (0.59 to 0.84) and a p-value of 0.00007. Objective response favored the combination as well, 53 percent against 40 percent. Overall survival is the harder number. The final analysis showed a hazard ratio of 0.85 — a trend toward benefit — but its 95 percent confidence interval (0.70 to 1.03) crosses 1.0, meaning the trial cannot rule out that there is no survival difference at all. FDA's approval rests on progression-free survival and response rate, an established regulatory pathway in oncology, but a physician weighing this combination against cabozantinib alone is weighing a proven tumor-control advantage against an unproven survival one — not the same conversation as choosing between two drugs that have both cleared that bar.

A Toxicity Profile That Adds Up

Grade 3 or higher adverse events were similar in overall frequency between arms — roughly 84 percent on the combination against 83 percent on cabozantinib — but the composition and consequences differed. Discontinuation for toxicity ran higher on the combination: belzutifan accounted for 16.8 percent and lenvatinib for 21.1 percent of combination-arm discontinuations, against 11.3 percent on cabozantinib alone. The combination brought its own specific burden — anemia at any grade in roughly 87 percent of patients (about 20 percent grade 3 or higher) and hypoxia at any grade in roughly 16 percent — in place of cabozantinib's more familiar diarrhea and skin toxicity. Belzutifan's label calls for a baseline oxygen saturation check before starting and periodic pulse oximetry monitoring, weighted toward the first month of treatment when hypoxia most often appears, alongside routine blood counts for anemia. That is a monitoring routine on top of lenvatinib's own requirements — blood pressure checks, urine protein monitoring, and liver function tests — for a practice that may already run those checks for lenvatinib but has not needed to add belzutifan's hypoxia surveillance until now.

The combination against the trial's own comparator

	Belzutifan + lenvatinib	Cabozantinib alone
Median progression-free survival	14.8 months	10.7 months
Objective response rate	53%	40%
Overall survival benefit	Numerical trend only; not statistically significant	Established comparator arm
Grade 3+ adverse events	~84%	~83%
Discontinued for toxicity	16.8% (belzutifan) / 21.1% (lenvatinib) of the combination arm	11.3%

LITESPARK-011 is the only head-to-head data between these two options; no NCCN category yet places the new combination relative to cabozantinib alone.

Where Cabozantinib Still Holds the Line

The most recent NCCN Kidney Cancer guideline update, issued before this approval, kept cabozantinib as a mainstay option for post-immunotherapy treatment while downgrading several other combinations used at this line — cabozantinib plus nivolumab, axitinib plus pembrolizumab, and lenvatinib plus pembrolizumab all moved from a preferred to a lower-preference category — and added single-agent lenvatinib as an option useful in select circumstances. That guideline predates this approval and says nothing about the new belzutifan-lenvatinib combination specifically; no NCCN category has yet been assigned to it, and no published guideline or trade commentary has yet weighed its efficacy gain against cabozantinib alone directly against the added toxicity and the unresolved survival question. Trade coverage since the 24 September approval has largely restated the trial's own numbers rather than offered independent analysis of where it should sit — a genuine gap, not a settled answer this article can round up to one.

What Hasn’t Caught Up Yet

Both drugs already carry individual specialty-pharmacy and prior-authorization requirements as previously marketed oncolytics, and nothing in the public record yet confirms whether payers will require a single joint authorization for the new combined label or continue to review each drug separately. Neither manufacturer has disclosed a combined list price for the doublet as of publication. None of that should be read as a reason to withhold the option from an appropriate patient — the efficacy data supporting it is solid — but a practice adding this combination to its formulary should expect the administrative side of prescribing it to lag the clinical approval, in the same way the guideline placement and the independent practice commentary have.

• Check baseline oxygen saturation and hemoglobin before starting, and set a pulse-oximetry and CBC monitoring schedule weighted toward the first month — belzutifan's hypoxia and anemia risk is additive to lenvatinib's own toxicity, not a substitute for it.
• Weigh the missing survival benefit explicitly with the patient: this is a documented gain in progression-free survival and response, not (yet) a documented gain in how long a patient lives.
• Don't assume a guideline category exists for this specific combination relative to cabozantinib alone — the most recent NCCN update predates this approval.
• Confirm prior-authorization and combined pricing before committing a patient to the regimen; neither has been publicly established for the new label as of this approval.

Frequently asked questions

What did FDA approve, and for whom?

On 24 September 2026, FDA approved belzutifan (Welireg, Merck) in combination with lenvatinib (Lenvima, Eisai) for adults with advanced clear-cell renal cell carcinoma who progressed on or after a PD-1 or PD-L1 inhibitor, or within six months of completing adjuvant PD-1 therapy. It is the first approved regimen pairing a HIF-2α inhibitor with a multitargeted TKI in this post-immunotherapy setting.

How does it compare with cabozantinib, the trial's own comparator?

In LITESPARK-011 (747 patients), the combination beat cabozantinib alone on median progression-free survival (14.8 vs. 10.7 months, HR 0.70, p=0.00007) and objective response (53% vs. 40%). Overall survival showed only a numerical trend (HR 0.85, 95% CI 0.70-1.03) that did not reach statistical significance. Grade 3 or higher adverse events were similar overall (about 84% vs. 83%), but treatment discontinuation for toxicity was higher on the combination.

What extra monitoring does belzutifan add?

Belzutifan carries its own hypoxia and anemia risks distinct from lenvatinib's known toxicities (hypertension, proteinuria, hepatotoxicity). FDA labeling calls for a baseline oxygen saturation check before starting and periodic pulse oximetry monitoring, with the closest surveillance typically in the first month, plus routine complete blood counts for anemia. In LITESPARK-011, any-grade anemia occurred in about 87% of patients on the combination and any-grade hypoxia in about 16%.

Where does this fit in current kidney cancer guidelines?

The most recent NCCN Kidney Cancer update, issued before this approval, still lists cabozantinib as a mainstay option after immunotherapy, while downgrading several other post-IO combinations and adding single-agent lenvatinib as an option “useful in certain circumstances.” No guideline yet specifically places this new combination relative to cabozantinib alone, and no published analysis yet weighs its efficacy gain against its added toxicity and unresolved survival benefit.